The first and only FDA approved tDCS at-home
treatment for depression
Flow FL-100 is an FDA-approved, home-based neuromodulation treatment for patients 18 and older with moderate to severe Major Depressive Disorder as a monotherapy or adjunct, without requiring prior medication failure.
Flow FL-100 is expected to be available in the US in the summer of 2026.
Sign up to stay informed:
Potential amplification when used as an adjunct†1
Results at 10 weeks from a multisite, double-blind, placebo-controlled randomised superiority trial demonstrate that Flow FL-100 is effective when used both as a standalone treatment and as an adjunct to antidepressant therapy.
Remission rates when used as an adjunct and standalone at Week 10†1
.png?width=2000&height=1384&name=Group%2017537%20(1).png "Group 17537 (1)")
Favorable safety profile
Flow FL-100 has shown a favorable safety profile to date, with both clinical trial1 and real-world user data suggesting a low incidence of adverse reactions. Based on real world evidence from >40,000 users, the self-reported incidence rate of side-effects is 4.5%2.
Favorable safety profile
Flow FL-100 has shown a favorable safety profile to date, with both clinical trial1 and real-world user data suggesting a low incidence of adverse reactions. Based on real world evidence from >40,000 users, the self-reported incidence rate of side-effects is 4.5%2.
Addressing risk in real-world clinical settings‡
In a real-world crisis care evaluation3, Flow FL-100 use was associated with up to a 75% reduction in reported suicidal ideation and avoided psychiatric hospital admissions, suggesting potential value as a supportive intervention for patients with acute depressive symptoms.
Change in distribution of Depression Severity after 3 weeks3‡
.png?width=2000&height=1298&name=Group%2017551%20(1).png "Group 17551 (1)")
Be first to receive updates as we roll out treatment availability in the US.
*Remission is defined as a score of <10 on MADRS. MADRS remission rate was a secondary endpoint of the study. The primary endpoint of the study reviewed between-group mean difference in HDRS-17 scores and was –2.3 points in favour of the active group (p=0.012).
†Comparison of monotherapy and adjunctive use of Flow FL-100 was a sub-analysis evaluation included as table 10 and 11 in the Empower Study.
‡Findings from this crisis care evaluation are based on outcomes assessed after 3 and 6 weeks of treatment. The FDA-pivotal clinical trial evaluated its primary endpoint at 10 weeks; this difference in timeframe reflects the design and operational context of the crisis care service evaluation.
Please see more information about Flow FL-100, including the FDA-approved labeling, available here.
References: 1. Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Nat Med (2024). 2. Data on file. Flow Neuroscience Real-world reports. 2025. 3. Griffiths, C., Abdalla, S., Mcconnochie, M. and Jiang, H. (2024). Open Journal of Psychiatry, 14, 514-527.
Safety information
The side effects of the Flow FL-100 reported in clinical studies were generally mild and transient. The main risks of the device are skin dryness, skin irritation or redness after prolonged use, transient headache, stinging, burning, or itching sensations at the stimulation site, and skin burns (typically in cases of electrode pad reuse or use of dried-out electrode pads which is not recommended).
© 2026 Flow Neuroscience